Association between Statin Use and Alzheimer’s Disease

Context: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been associated with a decreased risk for Alzheimer’s disease (AD). Objective: To evaluate the association between statin use and AD adjusted for comorbid medical conditions. Design: A nested case-control study. Patients: Patients at the Veterans Affairs Medical Center in Birmingham, Ala., USA with a new diagnosis of AD (cases) between 1997 and 2001 (n = 309) and age-matched non-AD controls (n = 3,088). Main Outcome Measure: Odds ratio for association between AD and statin use. Results: Statin users had a 39% lower risk of AD relative to nonstatin users (odds ratio 0.61, 95% confidence interval 0.42–0.87). This association appeared to be modified by the presence of certain chronic medical conditions (i.e., hypertension, ischemic heart disease and cerebrovascular disease) in that the reduced risk was observed among those with these diseases, whereas no association was observed among those without any of these conditions. Conclusions: In this study, following adjustment for confounding factors, a statistically significant inverse association between statin use and AD was observed. The results lend support to looking at AD outcomes in trials of statins to further evaluate their possible beneficial effects.

[1]  D. Sparks,et al.  Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease , 1990, Neurobiology of Aging.

[2]  W. Klein,et al.  Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. , 1996, The Journal of biological chemistry.

[3]  A. Hofman,et al.  Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study , 1997, The Lancet.

[4]  G C Roman,et al.  Brain infarction and the clinical expression of Alzheimer disease. , 1997, JAMA.

[5]  James A. Mortimer,et al.  Brain Infarction and the Clinical Expression of Alzheimer Disease-Reply , 1997 .

[6]  W. Markesbery,et al.  Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. , 1997, JAMA.

[7]  A. Hofman,et al.  Dietary fat intake and the risk of incident dementia in the Rotterdam study , 1997, Annals of neurology.

[8]  D. Sparks.  Coronary Artery Disease, Hypertension, ApoE, and Cholesterol: A Link to Alzheimer's Disease? , 1997, Annals of the New York Academy of Sciences.

[9]  A. Nissinen,et al.  Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. , 1998, Neuroepidemiology.

[10]  B. Strooper,et al.  Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R. Stewart,et al.  Cardiovascular factors in Alzheimer’s disease , 1998, Journal of neurology, neurosurgery, and psychiatry.

[12]  K. Prasad.  Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. , 1999, Circulation.

[13]  M. Pfeffer,et al.  Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. , 1999, Circulation.

[14]  R. Stewart,et al.  Vascular Risk Factors and Alzheimer's Disease , 1999, The Australian and New Zealand journal of psychiatry.

[15]  M. Pfeffer,et al.  Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein , 1999 .

[16]  D. R. Gross,et al.  Link between heart disease, cholesterol, and Alzheimer's disease: A review , 2000, Microscopy research and technique.

[17]  Rong Wang,et al.  Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model , 2000, Neurobiology of Disease.

[18]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[19]  M. Hennerici,et al.  Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Mayeux,et al.  Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. , 2001, American journal of epidemiology.

[21]  C. Bergmann,et al.  Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  C. Schweiger.  [Statins and the risk of dementia]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[23]  U. Das.  Statins and the prevention of dementia. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[24]  L. Launer.  Demonstrating the case that AD is a vascular disease: epidemiologic evidence , 2002, Ageing Research Reviews.

[25]  H. Dodge,et al.  Use of Lipid‐Lowering Drugs in Older Adults With and Without Dementia: A Community‐Based Epidemiological Study , 2002, Journal of the American Geriatrics Society.

[26]  R. Mayeux,et al.  The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function , 2002, Neurology.

[27]  E. Barrett-Connor,et al.  Serum lipoprotein levels, statin use, and cognitive function in older women. , 2002, Archives of neurology.

[28]  Kenneth Rockwood,et al.  Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. , 2002, Archives of neurology.

[29]  V. Hirth,et al.  The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.

[30]  R. Kalaria,et al.  Vascular Factors in Alzheimer's Disease , 2003, International Psychogeriatrics.